Return to search

United BioSource Buys Envision Pharma

United BioSource Corp., a Bethesda, Md.-based provider of evidence-based services and information to the pharma and life sciences markets, has acquired Envision Pharma, a UK-based provider of scientific communication services integration. No financial terms were disclosed, although a United BioSource regulatory filing indicates a price of around $3.74 million.


United BioSource has raised $153 million in private equity funding from firms like Grotech Capital Group, J.W. Whitney and Oak Investment Partners.



United BioSource Corporation (UBC) today announced the acquisition of Envision Pharma, a leading scientific communications and technology company based in Horsham, UK, with offices in Southport and Glastonbury, Conn. and Philadelphia, Pa. With a focus on the pharmaceutical and biotechnology industry, Envision integrates scientific communication services and targeted software applications that contribute to marketplace awareness and comprehension of compounds at launch and beyond.

UBC provides evidence-based solutions to support the development and commercialization of pharmaceuticals, biotechnology and medical devices. The acquisition of Envision Pharma expands the company's global presence and capability in the development and delivery of scientific communication.

Envision Pharma has two market-leading applications. Datavision